$OMIC
Singular Genomics Systems, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023005819 Filed on March 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $863.0K $765.0K $765.0K
YoY Change
Cost Of Revenue $807.0K $789.0K $789.0K
YoY Change
Gross Profit $56.00K -$24.00K -$24.00K
YoY Change
Gross Profit Margin 6.49% -3.14% -3.14%
Selling, General & Admin $13.20M $11.75M $47.26M
YoY Change 16.08% 14.95% 65.12%
% of Gross Profit 23578.57%
Research & Development $12.23M $10.76M $46.20M
YoY Change 14.89% 13.8% 41.48%
% of Gross Profit 21839.29%
Depreciation & Amortization $793.0K $721.0K $2.431M
YoY Change 72.02% 98.08% 114.56%
% of Gross Profit 1416.07%
Operating Expenses $25.43M $22.51M $93.46M
YoY Change 15.5% 14.4% 52.52%
Operating Profit -$25.38M -$22.53M -$93.49M
YoY Change 15.25% 52.56%
Interest Expense $259.0K $1.429M $763.0K
YoY Change 82.39% -1742.53% -9.81%
% of Operating Profit
Other Income/Expense, Net $1.745M $0.00 $2.608M
YoY Change 543.95%
Pretax Income -$23.63M -$21.10M -$90.88M
YoY Change 7.39% 6.79% -7.99%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$23.63M -$21.10M -$90.88M
YoY Change 7.39% 6.79% -7.99%
Net Earnings / Revenue -2738.47% -2758.3% -11879.61%
Basic Earnings Per Share -$0.33 -$1.28
Diluted Earnings Per Share -$0.33 -$0.29 -$1.28
COMMON SHARES
Basic Shares Outstanding 71.94M 71.40M 71.15M
Diluted Shares Outstanding 71.93M 71.15M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $226.5M $245.2M $245.2M
YoY Change -28.3% -27.72% -27.88%
Cash & Equivalents $129.3M $74.27M $74.27M
Short-Term Investments $97.26M $170.9M $170.9M
Other Short-Term Assets $2.752M $4.102M $4.102M
YoY Change -21.06% -51.95% -13.91%
Inventory $17.16M $18.22M $18.22M
Prepaid Expenses $2.120M $3.003M
Receivables $14.00K $913.0K $913.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $246.5M $268.4M $268.4M
YoY Change -24.35% -22.81% -22.81%
LONG-TERM ASSETS
Property, Plant & Equipment $11.26M $10.78M $56.68M
YoY Change 67.69% 77.6% 833.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.152M $1.152M $2.863M
YoY Change -45.79% 2.04% 57.65%
Total Long-Term Assets $59.00M $59.54M $59.54M
YoY Change 261.44% 654.86% 654.86%
TOTAL ASSETS
Total Short-Term Assets $246.5M $268.4M $268.4M
Total Long-Term Assets $59.00M $59.54M $59.54M
Total Assets $305.5M $328.0M $328.0M
YoY Change -10.71% -7.78% -7.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.977M $3.099M $3.099M
YoY Change -43.91% 31.98% 31.98%
Accrued Expenses $3.353M $4.583M $10.91M
YoY Change 15.18% 7.13% 154.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $12.49M $14.12M $14.12M
YoY Change 37.52% 109.34% 109.34%
LONG-TERM LIABILITIES
Long-Term Debt $10.10M $10.07M $10.07M
YoY Change 1.63% 1.63% 1.63%
Other Long-Term Liabilities $998.0K $1.015M $43.47M
YoY Change -42.25% -64.1% 1437.71%
Total Long-Term Liabilities $11.10M $11.08M $53.54M
YoY Change -4.87% -12.97% 320.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.49M $14.12M $14.12M
Total Long-Term Liabilities $11.10M $11.08M $53.54M
Total Liabilities $65.14M $67.65M $67.65M
YoY Change 164.49% 247.39% 247.39%
SHAREHOLDERS EQUITY
Retained Earnings -$266.4M -$242.8M
YoY Change 53.19% 59.84%
Common Stock $7.000K $7.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $240.3M $260.3M $260.3M
YoY Change
Total Liabilities & Shareholders Equity $305.5M $328.0M $328.0M
YoY Change -10.71% -7.78% -7.78%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$23.63M -$21.10M -$90.88M
YoY Change 7.39% 6.79% -7.99%
Depreciation, Depletion And Amortization $793.0K $721.0K $2.431M
YoY Change 72.02% 98.08% 114.56%
Cash From Operating Activities -$17.93M -$19.92M -$87.09M
YoY Change -9.6% 26.87% 68.46%
INVESTING ACTIVITIES
Capital Expenditures $162.0K $1.818M $6.022M
YoY Change -82.75% -202.71% 23.81%
Acquisitions
YoY Change
Other Investing Activities $73.11M $1.989M -$33.54M
YoY Change 683.99% -109.23% -73.38%
Cash From Investing Activities $72.95M $171.0K -$39.57M
YoY Change 769.84% -100.73% -69.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $279.0K
YoY Change -92.2%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.000K 750.0K 901.0K
YoY Change -73.91% -7.41% -99.76%
NET CHANGE
Cash From Operating Activities -17.93M -19.92M -87.09M
Cash From Investing Activities 72.95M 171.0K -39.57M
Cash From Financing Activities 6.000K 750.0K 901.0K
Net Change In Cash 55.02M -19.00M -125.8M
YoY Change -581.34% -50.29% -166.34%
FREE CASH FLOW
Cash From Operating Activities -$17.93M -$19.92M -$87.09M
Capital Expenditures $162.0K $1.818M $6.022M
Free Cash Flow -$18.10M -$21.73M -$93.12M
YoY Change -12.91% 56.04% 64.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001850906
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40443
CY2022 dei Entity Registrant Name
EntityRegistrantName
Singular Genomics Systems, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2948451
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
3010 Science Park Road
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2022 dei City Area Code
CityAreaCode
858
CY2022 dei Local Phone Number
LocalPhoneNumber
333-7830
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
OMIC
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
214000000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71941091
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
San Diego, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74266000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
201049000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
170310000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
138174000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
913000
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
0
CY2022Q4 us-gaap Inventory Net
InventoryNet
18221000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3011000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4722000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5526000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
268432000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
347760000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45896000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10784000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6072000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1711000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
687000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1152000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1129000
CY2022Q4 us-gaap Assets
Assets
327975000
CY2021Q4 us-gaap Assets
Assets
355648000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3099000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2348000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4583000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4278000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6323000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
113000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
118000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14118000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6744000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42456000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10065000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37492000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-90879000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9904000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1015000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2827000
CY2022Q4 us-gaap Liabilities
Liabilities
67654000
CY2021Q4 us-gaap Liabilities
Liabilities
19475000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71854688
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72438742
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
503926000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
488200000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-837000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242775000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151896000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260321000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
336173000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
327975000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355648000
CY2022 us-gaap Revenues
Revenues
765000
CY2021 us-gaap Revenues
Revenues
0
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
789000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
0
CY2022 us-gaap Gross Profit
GrossProfit
-24000
CY2021 us-gaap Gross Profit
GrossProfit
0
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46199000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32655000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47264000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28624000
CY2022 us-gaap Operating Expenses
OperatingExpenses
93463000
CY2021 us-gaap Operating Expenses
OperatingExpenses
61279000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-93487000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-61279000
CY2022 us-gaap Interest Expense
InterestExpense
763000
CY2021 us-gaap Interest Expense
InterestExpense
846000
CY2022 omic Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
0
CY2021 omic Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
35199000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2180000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
3371000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
733000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2608000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-98771000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.10
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.10
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71148076
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71148076
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47023048
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47023048
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-90879000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-98771000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-699000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-155000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91578000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98926000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-51555000
CY2021 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
798000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1160000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9231000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
69184000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
165699000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
237199000
CY2021 omic Cashless Exercise Of Common Stock Warrant Value
CashlessExerciseOfCommonStockWarrantValue
2631000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-155000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
752000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-98771000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
336173000
CY2022 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
705000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
172000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1180000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13669000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-699000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-90879000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260321000
CY2022 us-gaap Profit Loss
ProfitLoss
-90879000
CY2021 us-gaap Profit Loss
ProfitLoss
-98771000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
13669000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
9231000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3601000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-676000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1865000
CY2022 us-gaap Depreciation
Depreciation
2431000
CY2021 us-gaap Depreciation
Depreciation
1133000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
165000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
279000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-60000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-94000
CY2022 omic Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
0
CY2021 omic Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
35199000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2180000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
913000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13487000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75977000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201736000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
561000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
569000
CY2022 omic Initial Lease Liability Recognized Upon Lease Commencements
InitialLeaseLiabilityRecognizedUponLeaseCommencements
43231000
CY2021 omic Initial Lease Liability Recognized Upon Lease Commencements
InitialLeaseLiabilityRecognizedUponLeaseCommencements
0
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-604000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6851000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
892000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1048000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1168000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1854000
CY2022 omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
79000
CY2021 omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
2686000
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
81000
CY2021 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-176000
CY2022 omic Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1208000
CY2021 omic Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
0
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
87000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
624000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87094000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51701000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
174713000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
195684000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
119647000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
33688000
CY2022 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
21522000
CY2021 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
35999000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6022000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4864000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39566000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-130861000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1180000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
752000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
171000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3615000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
450000
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
237199000
CY2022 omic Proceeds From Issuance Of Convertible Promissory Notes
ProceedsFromIssuanceOfConvertiblePromissoryNotes
0
CY2021 omic Proceeds From Issuance Of Convertible Promissory Notes
ProceedsFromIssuanceOfConvertiblePromissoryNotes
130500000
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2021 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10500000
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
10400000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
901000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
372128000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-125759000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
189566000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201736000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12170000
CY2022 omic Initial Lease Liability Recognized Upon Adoption Of Asc842
InitialLeaseLiabilityRecognizedUponAdoptionOfAsc842
7074000
CY2021 omic Initial Lease Liability Recognized Upon Adoption Of Asc842
InitialLeaseLiabilityRecognizedUponAdoptionOfAsc842
0
CY2022 omic Purchases Of Inventory Included In Accounts Payable
PurchasesOfInventoryIncludedInAccountsPayable
1601000
CY2021 omic Purchases Of Inventory Included In Accounts Payable
PurchasesOfInventoryIncludedInAccountsPayable
0
CY2022 omic Noncurrent Desposit Transferred To Property And Equipment
NoncurrentDespositTransferredToPropertyAndEquipment
759000
CY2021 omic Noncurrent Desposit Transferred To Property And Equipment
NoncurrentDespositTransferredToPropertyAndEquipment
0
CY2022 omic Vesting Of Restricted Stock
VestingOfRestrictedStock
705000
CY2021 omic Vesting Of Restricted Stock
VestingOfRestrictedStock
798000
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
334000
CY2021 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
CY2022 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
318000
CY2021 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
67000
CY2022 omic Purchases Of Inventory Included In Accrued Expenses
PurchasesOfInventoryIncludedInAccruedExpenses
226000
CY2021 omic Purchases Of Inventory Included In Accrued Expenses
PurchasesOfInventoryIncludedInAccruedExpenses
0
CY2022 omic Inventory Transferred To Property And Equipment
InventoryTransferredToPropertyAndEquipment
104000
CY2021 omic Inventory Transferred To Property And Equipment
InventoryTransferredToPropertyAndEquipment
0
CY2022 omic Conversion Of Notes To Common Stock
ConversionOfNotesToCommonStock
0
CY2021 omic Conversion Of Notes To Common Stock
ConversionOfNotesToCommonStock
165699000
CY2022 omic Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
0
CY2021 omic Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
69184000
CY2022 omic Cashless Warrants Exercise
CashlessWarrantsExercise
0
CY2021 omic Cashless Warrants Exercise
CashlessWarrantsExercise
300000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242800000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151900000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
244600000
CY2022 omic Period Of Operations Sufficient To Fund
PeriodOfOperationsSufficientToFund
P12M
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
171147000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-837000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74266000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
201049000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1711000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
687000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75977000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201736000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
170310000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
138312000
CY2021Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-138000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
138174000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
155920000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
94085000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
14390000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
44089000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
170310000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
138174000
CY2022 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
three to five years
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Revenue Recognition Allowances
RevenueRecognitionAllowances
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company generates revenue from sales of products which consist of the G4 instrument, related consumable flow cell kits and services. Revenue from instrument sales is recognized generally upon customer acceptance. Revenue from consumables sales is recognized generally upon shipment to the customer. Revenue from services, which are primarily comprised of assurance-type services, is recognized over the applicable service period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recorded net of discounts and sales taxes. The Company invoices its customers for instruments generally upon acceptance, for consumables generally on delivery, and for services generally in advance of the service period. Invoice terms are generally net 30 days. Cash received from customers in advance of revenue recognition is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.</span></p><p style="text-indent:4.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company regularly enters into contracts that include a combination of products and services, which are distinct within the context of the contract and are accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. Until the Company has sufficient volume of historical sales data for each performance obligation, the Company determines the standalone selling price using observable prices when available and with consideration of current market conditions which is primarily based on prices set by management, adjusted for applicable discounts. The Company then recognizes revenue for each performance obligation as that performance obligations is satisfied as discussed above.</span></p><p style="text-indent:4.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022 and 2021, the Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of revenue related to sales of instruments and consumables products. Contract liabilities, which consists of deferred revenue, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and December 31, 2021 were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, were recorded as other noncurrent liabilities. Deferred revenue represents the value of performance obligations that have been invoiced but for which revenue has not yet been earned.</span></p><p style="text-indent:4.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, all of the Company’s revenue was generated within the United Sates. During the period, the Company generated all of its revenue from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
800000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
100000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2022 omic Number Of Customers
NumberOfCustomers
3
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8259000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4558000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2187000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10784000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6072000
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
7100000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6400000
CY2022Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
700000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
14508000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2565000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3276000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
446000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
437000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
0
CY2022Q4 us-gaap Inventory Net
InventoryNet
18221000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3011000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3003000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3715000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
1099000
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
1050000
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
620000
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
761000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4722000
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
5526000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15342000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3580000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3516000
CY2022Q4 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
360000
CY2021Q4 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
41000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
204000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
200000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
439000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
521000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4583000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4278000
CY2021Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
15000000.0
CY2022 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-09-01
CY2022 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.000075
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0400
CY2022 omic Debt Instrument Interest Rate Due On Maturity Date
DebtInstrumentInterestRateDueOnMaturityDate
0.0400
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
400000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
600000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10500000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10500000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
435000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
596000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
10065000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
9904000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
804000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2612000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5780000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4029000
CY2022Q4 omic Long Term Debt Maturities Repayments Of Principal Including Interest Payments
LongTermDebtMaturitiesRepaymentsOfPrincipalIncludingInterestPayments
13225000
CY2022Q4 omic Interest And Final Payment Fee
InterestAndFinalPaymentFee
2725000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
435000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
10065000
CY2022Q4 omic Accrued Payment Related To Milestone
AccruedPaymentRelatedToMilestone
400000
CY2022 omic Lease Termination Cost
LeaseTerminationCost
35000
CY2022Q1 omic Initial Lease Term
InitialLeaseTerm
P144M
CY2022Q1 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P60M
CY2022Q1 us-gaap Net Rentable Area
NetRentableArea
64.80
CY2022Q1 omic Annual Increases Percentage
AnnualIncreasesPercentage
0.03
CY2022Q1 omic Maximum Tenant Improvement Amount
MaximumTenantImprovementAmount
32900000
CY2022Q1 omic Tenant Improvements Amount
TenantImprovementsAmount
23700000
CY2022Q1 omic Improvements Interest Rate
ImprovementsInterestRate
0.07
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
1100000
CY2022Q1 us-gaap Security Deposit
SecurityDeposit
1100000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.036
CY2022Q1 omic Cash Payments
CashPayments
7500000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2022Q4 omic Cash Payments
CashPayments
86700000
CY2022 us-gaap Operating Leases Income Statement Initial Direct Costs
OperatingLeasesIncomeStatementInitialDirectCosts
9300000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
100000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
2700000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
6500000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
2200000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6552000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7765000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5560000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5565000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5447000
CY2022Q4 omic Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
55803000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
86692000
CY2022Q4 omic Operating Lease Future Minimum Payments Less Discount
OperatingLeaseFutureMinimumPaymentsLessDiscount
37913000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
48779000
CY2022Q4 omic Less Current Portion
LessCurrentPortion
6323000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42456000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
179000000.0
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Next Rolling Twelve Months
OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths
6552000
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Rolling Year Two
OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo
7765000
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Rolling Year Three
OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree
10902000
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Rolling Year Four
OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour
19346000
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Rolling After Year Five
OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive
19657000
CY2022Q4 omic Operating Leases Future Minimum Payments Thereafter
OperatingLeasesFutureMinimumPaymentsThereafter
201322000
CY2022Q4 omic Future Minimum Payments Total
FutureMinimumPaymentsTotal
265544000
CY2022Q1 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
0.0001
CY2022Q1 omic Percentage Of Amended Shares Of Common Stock
PercentageOfAmendedSharesOfCommonStock
0.049
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5322314
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.75
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3296183
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.03
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6587419
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.00
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
392824
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.47
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1879887
CY2022 omic Share Based Compensation Arrangements By Share Based Payment Award Options Forfeited In Period Weighted Average Forfeiture Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageForfeiturePrice
12.63
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9637022
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.35
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3223000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4066881
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.17
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3220000
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.01
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.01
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1300000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
74600000
CY2022Q4 omic Liability For Cash Received From Early Exercise Of Stock
LiabilityForCashReceivedFromEarlyExerciseOfStock
500000
CY2021Q4 omic Liability For Cash Received From Early Exercise Of Stock
LiabilityForCashReceivedFromEarlyExerciseOfStock
1700000
CY2022Q4 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
526660
CY2021Q4 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
2198933
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13669000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9231000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
27300000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5756
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7722
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0198
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0091
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17350014
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19085000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-20742000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2615000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3305000
CY2022 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
49000
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
1373000
CY2022 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
0
CY2021 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
7392000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-3434000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-3072000
CY2022 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
24423000
CY2021 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
17861000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
662000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
493000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40101000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27560000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9433000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6005000
CY2022Q4 omic Lease Liability
LeaseLiability
11673000
CY2021Q4 omic Lease Liability
LeaseLiability
39000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
7408000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
0
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3972000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1355000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
72587000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
34959000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59435000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
34844000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
13152000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
115000
CY2022Q4 omic Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
-10983000
CY2021Q4 omic Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
0
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2169000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
115000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
13152000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
115000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
24600000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17900000
CY2022 omic Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2021 omic Period For Cumulative Change In Ownership
PeriodForCumulativeChangeInOwnership
P3Y
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
866000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
493000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
50000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
18000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
421000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
355000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1237000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
866000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12663682
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7521247

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-005819-index-headers.html Edgar Link pending
0000950170-23-005819-index.html Edgar Link pending
0000950170-23-005819.txt Edgar Link pending
0000950170-23-005819-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img150904050_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
omic-20221231.htm Edgar Link pending
omic-20221231.xsd Edgar Link pending
omic-ex10_18.htm Edgar Link pending
omic-ex23_1.htm Edgar Link pending
omic-ex31_1.htm Edgar Link pending
omic-ex31_2.htm Edgar Link pending
omic-ex32_1.htm Edgar Link pending
omic-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
omic-20221231_cal.xml Edgar Link unprocessable
omic-20221231_def.xml Edgar Link unprocessable
omic-20221231_lab.xml Edgar Link unprocessable
omic-20221231_pre.xml Edgar Link unprocessable
omic-20221231_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending